Hospitals worried about impact of potential Walmart-Humana deal

Pressure from lower-priced healthcare options has already been hitting hospitals’ bottom lines. If Walmart’s early talks to acquire Humana come to fruition, that pressure would only intensify, according to the Wall Street Journal.

WSJ was the first to report Walmart—the world’s largest company by revenue—was looking to buy the $37 billion Humana. It would the largest of the vertical integrations proposed over the last few months which could all lead to keeping more patients out of the hospital. With inpatient admissions already an area of concern, Walmart’s massive retail presence could also siphon away more profitable outpatient business from health systems.

“What worries us is death by a thousand cuts,” said Randy Oostra, president and CEO of ProMedica, a Toledo, Ohio-based hospital system. “Another deal and another deal.”

Unlike other outside companies touted as healthcare disruptors, Walmart has a history of a “very sophisticated negotiator” on the care it provides for employees. Its experience with selective direct contracting with hospitals could inform a strategy to expand into care delivery.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.